Implantable Cardioverter-Defibrillators in Patients with ESRD: Complications, Management, and Literature Review.

BACKGROUND

Cardiovascular diseases are the leading cause of death among dialysis patients, accounting for about 40% of all their mortalities. Sudden cardiac death (SCD) is culpable for 37.5% of all deaths among patients with end-stage renal disease (ESRD). Implantable cardioverterdefibrillators (ICDs) should be considered in dialysis patients for the primary or secondary prevention of SCD. Recent studies on the implementation of ICD/cardiac resynchronization therapy do not exclude patients with ESRD; however, individualized decisions should be made in this group of patients. A thorough evaluation of the benefits of ICD implementation in patients with ESRD requires several large-scale mortality studies to compare and follow up patients with ESRD with and without ICDs. In the present study, we sought to determine and clarify the complications associated with ICD implementation and management thereof in patients suffering from ESRD.

METHODS

To assess the complications allied to the implementation of ICDs and their management in patients with ESRD, we reviewed available related articles in the literature.

RESULTS AND CONCLUSIONS

ICD implementation in dialysis patients has several complications, which has limited its usage. Based on our literature review, the complications of ICD implementation can be categorized as follows: (1) Related to implantation procedures, hematoma, and pneumothorax; (2) Related to the device/lead such as lead fracture and lead dislodgment; (3) Infection; and (4) Central vein thrombosis. Hence, the management of the complications of ICDs in this specific group of patients is of vital importance.